{"id":296420,"date":"2022-09-07T00:00:00","date_gmt":"2022-09-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0010-2022-biopharma-parkinsons-disease-access-reimbursement-access-reimbursement\/"},"modified":"2026-04-25T11:28:45","modified_gmt":"2026-04-25T11:28:45","slug":"acrecg0010-2022-biopharma-parkinsons-disease-access-reimbursement-access-reimbursement-parkinsons-disease-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0010-2022-biopharma-parkinsons-disease-access-reimbursement-access-reimbursement-parkinsons-disease-us\/","title":{"rendered":"Parkinson&#8217;s Disease &#8211; Access &#038; Reimbursement &#8211; Access &#038; Reimbursement &#8211; Parkinson&#8217;s Disease (US)"},"content":{"rendered":"<p>Since 2015, eight new brands have launched into the highly generic U.S. Parkinson\u2019s disease (<abbr title=\"Parkinson's disease\">PD<\/abbr>) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive disease pathology already drive a sizable cost burden for elderly patients (a growing population) and payers, and the impending launch of premium-priced brands will exacerbate these market conditions. Three novel subcutaneous pump therapies (ABBV-951 [AbbVie], <span class=\"abbreviation-guard\">ND<\/span>-0612 [NeuroDerm \/ Mitsubishi], and SPN-830 [Supernus]) offer potentially transformative motor symptom benefits for advanced <abbr title=\"Parkinson's disease\">PD<\/abbr> patients, while a range of novel adjunctive medications for niche populations (e.g., dyskinesia) are progressing through the pipeline. Anticipating payers\u2019 receptivity to emerging products\u2014some of which could be paradigm-altering\u2014and how future coverage policies could affect patient access and neurologists\u2019 treatment choice is crucial for drug developers entering an increasingly crowded, largely generic, and clinically complex market.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the current state of coverage for key <abbr title=\"Parkinson's disease\">PD<\/abbr> brands in the U.S. market? What restrictions do payers impose, and how do current market access dynamics influence surveyed neurologists\u2019 prescribing?<\/li>\n<li>How receptive are payers to therapies in late-phase development, such as AbbVie\u2019s ABBV-951 or Amneal\u2019s IPX-203? What coverage decisions do they anticipate? How do neurologists expect to prescribe these products?<\/li>\n<li>What market access and reimbursement challenges will emerging therapies face in the U.S. market? How will these challenges affect their uptake?<\/li>\n<li>What clinical scenarios drive the use of acute rescue therapies? Do neurologists prefer Kynmobi over Inbrija or Apokyn?<\/li>\n<\/ul>\n<p><strong>Product description:<\/strong><\/p>\n<p><em>U.S. Access &#038; Reimbursement<\/em> provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.<\/p>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>P<\/strong><strong>rimary research: <\/strong>Survey of 101 U.S. neurologists and 30 U.S. managed care organization (<abbr title=\"managed care organization\">MCO<\/abbr>) pharmacy and medical directors (<abbr data-abbreviation-entity=\"5531\" title=\"pharmacy director\">PD<\/abbr>s\/<abbr title=\"medical director\">MD<\/abbr>s)<\/p>\n<p><strong>Key drugs covered: <\/strong>ABBV-951, Duopa, Gocovri, Inbrija, IPX-203, Kynmobi, ND-0612, Nourianz, Nuplazid, Ongentys, Rytary, SPN-830, Xadago, all generic mainstays<\/p>\n<p><strong>Key companies: <\/strong>AbbVie, Acorda, Amneal, Kyowa Kirin, Mitsubishi, NeuroDerm, Sunovion, Supernus, UCB<\/p>\n","protected":false},"template":"","class_list":["post-296420","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-therapy-areas-parkinsons-disease","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296420\/revisions"}],"predecessor-version":[{"id":576211,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296420\/revisions\/576211"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}